Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

bayer limited - calcium carbonate; magnesium carbonate - chewable tablet - 680 mg/80 milligram(s) - magnesium carbonate; calcium carbonate; antacids, other combinations

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - zoledronic acid - concentrate for solution for infusion - 4 mg/5ml - bisphosphonates; zoledronic acid

Մալթա - անգլերեն - Medicines Authority

bayer plc - calcium carbonate; dimeticone; magnesium carbonate, heavy - chewable tablet - calcium carbonate 680 mg; dimeticone 25 mg; magnesium carbonate, heavy 80 mg - drugs for acid related disorders

Մալթա - անգլերեն - Medicines Authority

bayer public limited company 400 south oak way, reading berkshire rg2 6ad, united kingdom - calcium carbonate, magnesium carbonate, heavy - chewable tablet - calcium carbonate 680 mg magnesium carbonate, heavy 80 mg - drugs for acid related disorders

Մալթա - անգլերեն - Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - zoledronic acid, monohydrate - concentrate for solution for infusion - zoledronic acid monohydrate 4 mg/5ml - drugs for treatment of bone diseases

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

accord healthcare s.l.u. - zoledronic acid monohydrate - hypercalcemia; fractures, bone; cancer - bisphosphonates - prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.treatment of adult patients with tumour-induced hypercalcaemia (tih).

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

pfizer europe ma eeig - zoledronic acid monohydrate - hypercalcemia - drugs for treatment of bone diseases - 4 mg / 5 ml and 4 mg / 100 ml:prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.treatment of adult patients with tumour-induced hypercalcaemia (tih).5 mg / 100 ml:treatment of osteoporosis:in post-menopausal women;in men;at increased risk of fracture, including those with a recent low-trauma hip fracture.treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:in post-menopausal women;in men;at increased risk of fracture.treatment of paget's disease of the bone in adults.

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

mylan pharmaceuticals limited - zoledronic acid - fractures, bone - drugs for treatment of bone diseases - prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (tih).

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

heritage pharmaceuticals inc. - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 5 mg in 100 ml - zoledronic acid injection is indicated for treatment of paget's disease of bone in men and women. treatment is indicated in patients with paget's disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see clinical studies (14.5) ]. zoledronic acid injection is contraindicated in patients with the following conditions: - hypocalcemia [see warnings and precautions (5.2) ] - creatinine clearance less than 35 ml/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see warnings and precautions (5.3) ]. - known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. hypersensitivity reactions including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see post-marketing experience (6.2) ]. pregnancy category d [see warnings and precautio

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - zoledronic acid monohydrate, quantity: 0.8528 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium citrate dihydrate; mannitol - ? prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone.,? treatment of tumour-induced hypercalcaemia.